Polyclonal Antibody to Sclerostin Domain Containing Protein 1 (SOSTDC1)
| Code | Size | Price |
|---|
| PAF900Hu01-20ul | 20ul | £87.00 |
Quantity:
| PAF900Hu01-100ul | 100ul | £162.00 |
Quantity:
| PAF900Hu01-200ul | 200ul | £218.00 |
Quantity:
| PAF900Hu01-1ml | 1ml | £499.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Human
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
CDA019; USAG1; Ectodin; Ectodermal BMP inhibitor; Uterine sensitization-associated gene 1 protein
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Sclerostin Domain Containing Protein 1
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-5ug/mL;<br/>Immunohistochemistry: 5-50ug/mL;<br/>Immunocytochemistry: 5-50ug/mL;<br/>Optimal working dilutions must be determined by end user.
References
https://www.tandfonline.com/doi/abs/10.1080/15384101.2021.1924947;
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Sclerostin Domain Containing Protein 1 (SOSTDC1) | RPF900Hu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||